Product Detailed Description

Liposomal vitamin E 30% DL-Alpha-Tocopherol — High Bioavailability Antioxidant Supplement

Product Overview

liposomal Vitamin E 30% is a premium-grade dietary supplement ingredient delivering DL-alpha-tocopherol in an advanced liposomal delivery system. DL-Alpha-Tocopherol (CAS 2074-53-5), also known as all-rac-α-tocopherol, synthetic vitamin E, or racemic α-tocopherol, is a fat-soluble antioxidant with the molecular formula C₂₉H₅₀O₂ and a molecular weight of 430.71 g/mol. The compound is chemically designated as (RS)-2,5,7,8-tetramethyl-2-((4RS,8RS)-4,8,12-trimethyltridecyl)chroman-6-ol and consists of eight stereoisomers in equal amounts, forming a racemic mixture. DL-α-Tocopherol occurs as a pale yellow to yellow, clear, viscous oil that is practically insoluble in water, freely soluble in ethanol, and miscible with fats and oils.

The 30% specification for this product represents the Active Ingredient Loading Capacity by weight relative to the total liposomal formulation. Research has demonstrated that liposomes made with a French pressure cell can contain no more than 33 mol% of tocopherol, and liposomes containing α-tocopherol at 15 to 30 mol% may be useful for delivering physiological quantities of this vitamin to cells in culture or to tissues in vivo. This designation allows formulators to select the optimal balance between active potency and formulation stability for their specific application.

Why Liposomal Technology?

Conventional oral vitamin E presents significant bioavailability challenges. Vitamin E is a highly lipophilic molecule that requires bile salt-mediated micelle formation for intestinal absorption, and its absorption is influenced by dietary fat intake and individual gastrointestinal conditions. Additionally, vitamin E is subject to extensive first-pass metabolism in the liver, which reduces the fraction of absorbed vitamin reaching systemic circulation.

Liposomal encapsulation provides four critical advantages:

1. Enhanced Plasma Persistence and Bioavailability — In a comparative pharmacokinetic study in postpubertal Friesian heifers, α-tocopherol encapsulated in liposomes exhibited a lower elimination rate constant (Kd) compared with α-tocopherol in oil or cyclodextrin formulations, suggesting that the liposomal formulation may result in longer persistence of the vitamin in plasma than the other preparations. The study concluded that dietary supplementation with α-tocopherol encapsulated in liposomes may enhance plasma availability of this vitamin and could be useful during periods of increased vitamin E requirements.

2. Enhanced Lymphatic Absorption — A study evaluating the incorporation of α-tocopherol in marine lipid-based liposomes demonstrated that α-tocopherol recovery in lymph was increased by almost threefold following liposome administration compared to non-liposomal delivery. This finding supports the role of liposomal encapsulation in enhancing lymphatic absorption and bypassing first-pass hepatic metabolism.

3. Protection from Gastric Degradation and Oxidation — The phospholipid bilayer shields vitamin E from gastric acid and enzymatic degradation, allowing direct absorption into the lymphatic system and cells. The liposomal shell prevents oxidation of tocopherol during storage and gastrointestinal transit, enabling a sustained release for long-lasting antioxidant protection.

4. Water-Dispersible and Clean-Label Compatible — The liposomal powder disperses readily in aqueous systems, forming a homogeneous, translucent and opalescent dispersion free from visible particulate matter. The phospholipid carrier is plant-derived and non-GMO, supporting clean-label positioning.

Product Specifications

Key Features

• High Purity — Standardized to 30% active ingredient loading capacity by weight relative to the total liposomal formulation, ensuring a balanced ratio of phospholipid carrier for optimal stability in aqueous dispersions.

• Liposomal Enhancement — Liposomal encapsulation significantly increases α-tocopherol recovery in lymph by almost threefold following liposome administration, and demonstrates a lower elimination rate constant (Kd) indicating longer plasma persistence compared with oil or cyclodextrin formulations.

• Potent Lipid Antioxidant — Vitamin E neutralizes reactive oxygen species (ROS) and prevents lipid peroxidation in cell membranes, protecting polyunsaturated fatty acids (PUFAs) and low-density lipoproteins (LDL) from oxidative damage.

• Cardiovascular Health Support — Vitamin E supports healthy blood vessel function and helps maintain optimal cholesterol levels through its antioxidant protection of LDL particles.

• Skin Protection — Vitamin E shields the skin from oxidative stress caused by UV radiation and environmental pollutants, supporting skin barrier integrity and reducing signs of photoaging.

• Cellular Longevity Support — Vitamin E enhances cellular resilience and supports healthy aging through superior biological activity and protection of cellular membranes.

• FDA GRAS Status — DL-α-Tocopherol is Generally Recognized as Safe (GRAS) by the FDA under 21 CFR § 184.1890 for use as a direct human food ingredient.

• Water-Dispersible — Liposomal powder offers excellent dispersibility in aqueous systems; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

The Recommended Dietary Allowance (RDA) for vitamin E is 15 mg/day (22.4 IU) for adults, which is equivalent to 15 mg of α-tocopherol. The Tolerable Upper Intake Level (UL) for supplemental vitamin E is 1,000 mg/day (approximately 1,500 IU of natural source or 1,100 IU of synthetic source) for adults. For supplemental use, vitamin E is commonly used at 100–400 IU/day for general antioxidant support. Higher doses of 400–800 IU/day have been used in clinical research for specific applications such as cardiovascular health and non-alcoholic fatty liver disease under medical supervision. For deficiency treatment, a baseline dose of 50 IU/day (maximum 300 IU) has been used, with up to 800 mg daily divided into two doses for ataxia with vitamin E deficiency (AVED). Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability and lymphatic absorption.

Important Safety Information: Vitamin E is generally well tolerated at recommended doses. The Tolerable Upper Intake Level (UL) for supplemental vitamin E is 1,000 mg/day for adults. High-dose vitamin E supplementation may increase the risk of bleeding, particularly in individuals taking anticoagulant or antiplatelet medications. All authorised forms of α-tocopherol are eligible for use, both free or esters, natural and synthetic, but it is well-established that high doses of α-tocopherol increase the risk of bleeding. Individuals with vitamin K deficiency or bleeding disorders should consult a healthcare professional before use. Vitamin E supplementation should be discontinued at least 2 weeks before surgery. Pregnant or lactating women and children should consult a healthcare professional before use. Vitamin E may interact with certain medications, including warfarin, aspirin, and chemotherapy agents.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.